Treatment of early Parkinson's disease. Part 1.
Simuni, T, KE Lyons, R Pahwa, RA Hauser, C Comella, L Elmer, and D Weintraub. 2009. “Treatment of Early Parkinson’s Disease. Part 1.”. Eur Neurol.
Search
Search results
134 results found
Levodopa: past, present, and future
Hauser, RA. 2009. “Levodopa: Past, Present, and Future”. Eur Neurol.
A pilot, double-blind, placebo-controlled trial of pregabalin (lyrica) in the treatment of essential tremor.
Zesiewicz, TA, CL Ward, RA Hauser, JL Salemi, S Siraj, MC Wilson, and KL Sullivan. 2007. “A Pilot, Double-Blind, Placebo-Controlled Trial of Pregabalin (lyrica) in the Treatment of Essential Tremor.”. Mov Disord.
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
Group, Parkinson Study, and RA Hauser. 2007. “Mixed Lineage Kinase Inhibitor CEP-1347 Fails to Delay Disability in Early Parkinson Disease.”. Neurology.
End-of-dose wearing off in Parkinson disease: a 9-question survey assessment.
Stacy, M, RA Hauser, W Oertel, A Shapira, K Sethi, F Stocchi, and E Tolosa. 2006. “End-of-Dose Wearing off in Parkinson Disease: A 9-Question Survey Assessment.”. Clin Neuropharmacol.
Levetiracetam-Induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol 2005;28:188-190.
Zesiewicz, TA, J Sanchez-Ramos, KL Sullivan, and RA Hauser. 2005. “Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient. Clin Neuropharmacol 2005;28:188-190.”. Clin Neuropharmacol.
Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005;11:469-471.
Sullivan, KL, RA Hauser, ED Louis, G Chari, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Generalized Dystonia. Parkinsonism Relat Disord 2005;11:469-471.”. Parkinsonism Relat Disord.
Parkinson's disease home diary: further validation and implications for clinical trials. Movement Disorders 2004;19:1409-1413.
Hauser, RA, F Deckers, and P Lehert. 2004. “Parkinson’s Disease Home Diary: Further Validation and Implications for Clinical Trials. Movement Disorders 2004;19:1409-1413.”. Movement Disorders.
Sleep attacks and dopamine agonists for Parkinson’s disease: What is currently known? CNS Drugs 2003;17:593-600.
Zesiewicz, TA, and RA Hauser. 2003. “Sleep Attacks and Dopamine Agonists for Parkinson’s Disease: What Is Currently Known? CNS Drugs 2003;17:593-600.”. CNS Drugs.
Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93-101.
Whone, AL, RL Warrs, AJ Stoessl, M Davis, S Reske, C Nahmias, AE Lang, et al. 2003. “Slower Progression of Parkinson’s Disease With Ropinirole versus Levodopa: The REAL-PET Study. Ann Neurol. 2003;54:93-101.”. 2003.